These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26014906)

  • 1. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.
    Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2015 Aug; 42(3):258-72. PubMed ID: 26014906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
    Nam HC; Lee HL; Yang H; Song MJ
    Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
    Hayes CN; Imamura M; Chayama K
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):103-113. PubMed ID: 27936974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
    Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
    Smith MA; Regal RE; Mohammad RA
    Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
    Hézode C; Chevaliez S; Scoazec G; Soulier A; Varaut A; Bouvier-Alias M; Ruiz I; Roudot-Thoraval F; Mallat A; Féray C; Pawlotsky JM
    Hepatology; 2016 Jun; 63(6):1809-16. PubMed ID: 26853230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asunaprevir for hepatitis C: a safety evaluation.
    Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
    Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C virus genotype 3-infection.
    Pol S; Vallet-Pichard A; Corouge M
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
    Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
    Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.